Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549	
-------------	------	-------	--

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* SATO VICKI L					2. Issuer Name and Ticker or Trading Symbol Denali Therapeutics Inc. [DNLI]										all app Direc		ig Per	son(s) to Is 10% Ov	wner
(Last) (First) (Middle) C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD.						3. Date of Earliest Transaction (Month/Day/Year) 08/18/2021									below)		below)		specify
(Street) SOUTH FRANCI	- (A 9	14080		4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	Form filed by More than One Reporting Person Person				
(City)	(5		Zip)																
		Table	I - No	on-Deriva	tive S	Secu	rities	Acc	quired	l, Dis	sposed of	, or B	enefic	cially	Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/N				.	Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acc Disposed Of (D)					and 5) Securi Benefi Owned		ties cially I Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price		Report Transa (Instr. :	orted isaction(s) tr. 3 and 4)			(Instr. 4)
Common Stock 08/18/20)21	21		S ⁽¹⁾		806	D	\$51.	26 ⁽²⁾ 132		2,025(3)		D		
Common Stock 08/18/20)21	21		S ⁽¹⁾		860	D	\$52.	.12 ⁽⁴⁾ 1		31,165 ⁽³⁾		D		
		Ta	ble II								osed of, convertib				Owne	t			
Derivative Conversion Da		Date Exec (Month/Day/Year) if any				action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/		ate	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Der Sec (Ins	rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	, (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exerci	isable	Expiration Date		Amount or Number of Shares						

Explanation of Responses:

- 1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- 2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$50.79 to \$51.77 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 3. Includes 2,074 restricted stock units.
- 4. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from \$51.86 to \$52.395 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Remarks:

/s/ Tyler Nielsen, by power of attorney

08/20/2021

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.